Podcasts about ADC

In 2025, the FDA approved the antibody-drug conjugate (ADC) enfortumab vedotin combined with pembrolizumab for patients with cisplatin-ineligible muscle-invasive bladder cancer, unlocking a new perioperative treatment option. To administer this ADC-based therapy alongside surgical intervention, multidisciplinary teams must prioritize collaborative workflows at all points of the treatment journey. In this episode, CANCER BUZZ speaks with Manojkumar Bupathi, MD, President of Rocky Mountain Cancer Centers, about how ADCs are reshaping the care model toward earlier, structured collaboration between urology and medical oncology. Guests: Manojkumar Bupathi, MD President Rocky Mountain Cancer Centers Co-Chair, GU Executive Committee Sarah Cannon Research Institute Denver, CO "The challenge wasn't learning the drug itself. The challenge was how you integrate the regimen into your treatment paradigm." —Manojkumar Bupathi, MD "There's always this relationship that happens from the beginning and is maintained throughout the entire process." —Manojkumar Bupathi, MD Resources: ACCC Bladder Cancer Resources ACCC Antibody-Drug Conjugate Resources  

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into an array of groundbreaking advancements and strategic movements reshaping the landscape of healthcare and medicine. Recent strides in Alzheimer's research have highlighted Biogen's promising Phase 2 clinical trial results for diranersen, an antisense oligonucleotide targeting the tau protein. Unlike traditional amyloid-targeting therapies, this approach offers a novel mechanism that could diversify treatment options for Alzheimer's patients. By addressing tau pathology, a critical feature of Alzheimer's disease, Biogen's findings may influence research trajectories and potentially lead to improved patient outcomes. In tandem with this, Biogen and Eisai have received FDA approval for a subcutaneous formulation of Leqembi (lecanemab), targeting amyloid-beta plaques. This new delivery method is poised to enhance patient compliance and accessibility, marking significant progress in broadening Alzheimer's treatment modalities. In oncology, AstraZeneca has entered into a substantial $1.5 billion licensing agreement with Dizal Pharmaceutical for lung cancer therapies. This strategic partnership emphasizes the importance of collaborative efforts in advancing cancer treatment and highlights the role of targeted therapies in addressing unmet medical needs. Additionally, Merck KGaA's Erbitux has secured European Commission approval for first-line treatment of BRAF V600E-mutant metastatic colorectal cancer. By focusing on specific genetic mutations, this approval illustrates the shift towards precision medicine, where treatments are tailored based on individual genetic profiles. The industry is also embracing advanced technologies such as artificial intelligence (AI) to enhance drug discovery processes. Chai Discovery's partnership with Novartis exemplifies this trend, as they focus on AI-driven therapeutic antibody discovery. Meanwhile, Ardigen and Veraxa Biotech's collaboration in optimizing T-cell engager and ADC drug discovery demonstrates AI's growing role in reducing timeframes and costs associated with bringing new therapies to market. Regulatory updates from the FDA seek to streamline registration rules to alleviate manufacturing burdens for biopharma companies, reflecting ongoing efforts to improve operational efficiencies in drug production. Additionally, new guidance on psychedelics indicates a regulatory openness that could stimulate innovation within neurological therapeutics. In other news, HUYABIO's Phase 3 trial results have shown promise for advanced skin cancer patients through a combination therapy involving Bristol Myers Squibb's Opdivo. This success underscores the potential of combination therapies to enhance treatment efficacy. Meanwhile, cell therapy is experiencing a transformative shift with Cellares' advancements in automating manufacturing processes. These innovations promise broader access to life-saving cell therapies by accelerating production timelines and reducing costs. Turning to business developments, Spero Therapeutics' $1.1 billion deal with Innovent Biologics marks a strategic pivot towards immune modulation therapies, highlighting the growing interest in autoimmune diseases. Concurrently, Avere Therapeutics' public listing via a reverse merger with NextCure and acquisition of an IL-23 drug signifies ongoing consolidation within the sector. On the regulatory front, Beckman Coulter's expansion of its Alzheimer's diagnostic portfolio through a CE mark for its p-tau217 assay enhances diagnostic capabilities crucial for early detection and management amid an aging global population. As we look globally, cities like Basel and Beijing are emerging as biotech hubs, attracting top talent and investments while fostering innovation. Amid these shifts, industry professionals are encouraged to adapt to evolving technological landscapes, particularly with AI poised to enhance decision-making processes and streamline clinical workflows. These developments illustrate a dynamic phase for pharma and biotech sectors where scientific breakthroughs are closely intertwined with strategic business decisions and regulatory advancements. As we continue to navigate these changes, the potential for delivering more effective treatments across various therapeutic areas is immense. Stay tuned as we bring you more insights into how these innovations are shaping the future of healthcare globally. Thank you for joining us at Pharma Daily; until next time.Support the show

As political parties prepare for the 2027 general election, unity may prove just as important as popularity.But a fresh Appeal Court ruling involving the African Democratic Congress (ADC) has raised questions about the party's internal leadership and what lies ahead.Today on Nigeria Daily, we ask: What does the Appeal Court ruling really mean for the ADC?I am Luqman Awwal Agono. My guests are Bolaji Abdullahi, National Publicity Secretary of the African Democratic Congress (ADC); Paul Ibe, spokesperson to former Vice President Atiku Abubakar; and Mr. David West, political analyst.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of transformative updates and strategic shifts within the industry, reflecting both remarkable progress and inherent challenges. Sanofi's recent achievement marks a significant milestone in oncology with the FDA approval of Sarclisa Escena (isatuximab) as the first on-body injector for multiple myeloma treatment. This monoclonal antibody, targeting CD38, offers a novel subcutaneous delivery method, simplifying administration and potentially enhancing patient compliance by reducing the need for frequent clinic visits. This aligns with the industry's ongoing shift towards patient-friendly drug delivery systems, emphasizing convenience without compromising efficacy. In another promising development, GSK and Hansoh Pharmaceutical have reported positive results from their Phase 3 trial evaluating risvutatug rezetecan for small cell lung cancer. This antibody-drug conjugate, targeting B7-H3, has shown potential when combined with chemotherapy to extend patient survival. Given the aggressive nature of small cell lung cancer and limited treatment options, these findings underscore the potential of targeted therapies to improve clinical outcomes significantly. Forte Biosciences' FB102 also takes a spotlight in clinical advancements. In its Phase 1b trial for vitiligo, FB102 demonstrated a 45.8% placebo-adjusted benefit. This monoclonal antibody works by modulating immune responses through the IL-15 pathway via CD122, offering new hope for patients with this challenging autoimmune condition. On the regulatory front, ARPA-H's commitment of up to $160 million towards developing personalized genetic medicines for rare diseases is noteworthy. This investment is set to accelerate innovations in gene therapy and personalized medicine platforms. Such advancements promise to revolutionize pediatric care and extend beyond by tailoring treatments to individual genetic profiles, enhancing efficacy while minimizing adverse effects. Strategic collaborations continue to reshape the industry landscape. Rani Therapeutics' partnership with PegBio aims at advancing oral delivery systems for obesity and metabolic diseases. Similarly, Simcere Pharmaceutical's collaboration with Schrödinger leverages AI-driven drug discovery efforts. These alliances highlight an increased reliance on computational platforms to streamline therapeutic development processes. From a financial perspective, Mesoblast Limited reports substantial revenue from its cell therapy product Ryoncil, signaling strong commercial viability for cell-based treatments targeting rare diseases. Additionally, Cue Biopharma's successful $50 million fundraising underscores investor confidence in advancing therapies for immunological disorders. However, not all news is positive. Roche has decided to halt two programs targeting Huntington's disease due to inadequate efficacy and safety concerns. This decision reflects the complexities involved in developing effective treatments for neurological disorders—a field fraught with scientific challenges yet rich with potential rewards. In market dynamics, McKinsey's report advocates for a structural redesign of biopharmaceutical R&D to fully leverage AI's capabilities. This recommendation resonates with current industry trends focusing on strategic innovation to maximize efficiency and discovery potential. The FDA's third rejection of Hengrui Pharma and Elevar Therapeutics' combination therapy for liver cancer underscores the rigorous scrutiny such treatments face despite their promise in addressing complex cancers. In contrast, BioNTech's preparation to launch its HER2 antibody-drug conjugate (ADC) signifies its strategic pivot back towards oncology after mRNA vaccine successes. Bayer's decision to sell a minority stake in its contraceptives business demonstrates how companies are strategically realigning portfolios to focus on core areas while securing funding for innovation. This move reflects broader trends within pharma as companies navigate financial landscapes to support long-term research goals. Amid these developments, regulatory environments continue evolving. NICE's stance against future Lumakras reimbursement in the UK highlights ongoing challenges in balancing cost-effectiveness with access to innovative therapies. Meanwhile, ARPA-H's significant funding allocation signals robust governmental support for advancing precision medicine within genetic therapies. In conclusion, today's updates reveal an industry characterized by a relentless pursuit of innovation amidst complex regulatory landscapes. As companies navigate these dynamics through strategic collaborations and scientific breakthroughs, their efforts hold promise for enhancing patient care across diverse therapeutic areas globally. Stay tuned as we continue to track these exciting developments shaping the future of pharmaceuticals and biotechnology. Thank you for tuning into Pharma Daily—your go-to source for up-to-date insights from the world of pharmaceuticals and biotechnology.Support the show

On this week's episode, Sam Fazeli, Josh Schimmer, Eric Schmidt, Paul Matteis, and special guest STAT's Matt Herper open on the market, noting that despite a wobbly day for biotech, the XBI holds strong gains year-to-date. The conversation turns to FDA transparency, where the co-hosts flag that CRLs haven't been released since April and that the agency may be walking back that practice. The co-hosts debate whether the FDA is swinging too far toward leniency after Agios' mitapivat won priority review in sickle cell disease despite missing its primary endpoint last year. On AI in drug discovery, Matt Herper recaps an interview with Anthropic's CEO about a new research tool, noting that it's plausible the tool helps industry pick better targets and lower the failure rate. In M&A, Vertex's largest-ever deal takes Crinetics for $10 billion net of cash, staking a claim in the specialty rare endocrine space, while Novartis expands its ADC portfolio with Myricx for $1.1 billion upfront plus $400 million in milestones — the second European ADC deal in recent months. On data, AstraZeneca and Ionis' eplontersen trial in ATTR-CM missed its endpoint, showing no benefit or biomarker signal on top of background tafamidis; the group then discusses the readthroughs for BridgeBio, Alnylam, and Pfizer's ATTR therapies. This episode aired on July 10, 2026.

En este episodio especial de BreastLink, el Dr. Juan Carlos Samamé conduce un análisis sobre las principales novedades en cáncer de mama presentadas en la reunión anual de la Sociedad Americana de Oncología Clínica. Para ello, cuenta con la participación de dos destacados referentes internacionales: el Dr. Antonio Llombart, del Hospital Arnau de Vilanova de Valencia, y el Dr. Fernando Petracci, del Instituto Alexander Fleming de Buenos Aires y presidente de la Asociación Latinoamericana de Cáncer de Mama. La discusión se centra en la evolución de los esquemas terapéuticos hacia una medicina cada vez más personalizada, destacando la consolidación de la desescalada terapéutica en enfermedad temprana y la optimización de las líneas de tratamiento en etapas avanzadas.Durante la revisión del subtipo HER2 positivo, el Dr. Llombart destaca la maduración de datos en estrategias de mantenimiento para enfermedad metastásica (estudios HER2CLIMB y PATINA), así como la exploración de la "respuesta parcial profunda" en primera línea. En el ámbito de la temprana, resalta el creciente interés en la desescalada terapéutica apoyada en estudios como PHERGain-2, que evalúa el doble bloqueo con trastuzumab y pertuzumab sin quimioterapia en tumores pequeños.Por su parte, en el panorama de los tumores luminales, el Dr. Petracci subraya la relevancia del estudio OPTIMA. Este ensayo de no inferioridad, guiado por la firma genómica PAM50, plantea un posible cambio en la práctica clínica al demostrar que es seguro omitir la quimioterapia en un subgrupo de pacientes de alto riesgo. Adicionalmente, se discuten las actualizaciones sobre los SERDs, con menciones a los estudios lidERA (giredestrant) y PERSEVERA (elacestrant).Finalmente, en el contexto del cáncer de mama triple negativo, se analizan los datos de seguimiento a largo plazo del estudio KEYNOTE-522 y el impacto real de mantener pembrolizumab en la fase adyuvante en pacientes que ya han alcanzado una respuesta completa patológica. Se exploran también resultados en enfermedad avanzada, como la combinación de sacituzumab govitecán con pembrolizumab (ASCENT-04) y la incursión de nuevos anticuerpos conjugados biespecíficos dirigidos a EGFR y HER3.El panel concluye reflexionando sobre los retos de incorporar estas plataformas moleculares, los nuevos ADC y biomarcadores emergentes, como el ctDNA en la toma de decisiones clínicas rutinarias.Referencia:Este contenido se basa en la interpretación crítica de la evidencia científica disponible, así como en la experiencia clínica del o los ponentes como profesionales de la salud en instituciones de referencia. Para profundizar en los conceptos discutidos, se recomienda al profesional de la salud consultar literatura científica vigente, guías clínicas internacionales y la normatividad aplicable en su país.

n este episodio especial de Chicago 2026: Lo más destacado en Tumores Ginecológicos, centrado en la evidencia más relevante de la reunión anual de la Sociedad Americana de Oncología Clínica, la Dra. Laura Venegas y el Dr. Eduardo González, expertos en ginecología oncológica, analizan las actualizaciones más relevante en tumores ginecológicos.El debate principal destaca la consolidación de los conjugados anticuerpo-fármaco (ADC) y su expansión hacia líneas más tempranas de tratamiento. En el contexto del cáncer de ovario platino-resistente y platino-sensible, se evalúa la eficacia de nuevos blancos terapéuticos como HER2 (estudio T-Bren), c-MET, y la combinación de mirvetuximab con carboplatino (estudio MIROVA). Además, se discuten los avances en terapias dirigidas no citotóxicas, incluyendo el inhibidor multiquinasa chiauranib (estudio CHIPOR), el antagonista de receptores de glucocorticoides relacorilant (estudio ROSELLA) y los inhibidores de CDK2 (estudio MAESTRA-2).En el ámbito de la inmunooncología, el episodio aborda enfoques para transformar el microambiente tumoral del cáncer de ovario, tradicionalmente considerado “inmunológicamente frío”. Se analizan los resultados de terapias celulares autólogas contra PRAME (IMA203CD8), vacunas de neoantígenos como mantenimiento (PESCO y estudio 122101) y la inhibición dual con anticuerpos anti-CTLA-4 como gotistobart combinado con pembrolizumab (PRESERVE-004). Por otro lado, en el cáncer de endometrio, se consolida el estándar de tratamiento en primera línea mediante la presentación de los datos de supervivencia a largo plazo (4 años de seguimiento) de los estudios fase III RUBY (dostarlimab) y NRG-GY018 (pembrolizumab), subrayando su potencial curativo en la población con dMMR.Finalmente, el análisis se extiende al cáncer cervicouterino recurrente o metastásico, un escenario con necesidades clínicas no cubiertas donde las terapias estándar tras la progresión son limitadas. La introducción de ADC de nueva generación dirigidos contra Trop-2 y Nectina-4 emerge como una estrategia prometedora. La sesión concluye haciendo énfasis en que el principal reto a corto plazo para la comunidad oncológica será la adecuada secuenciación terapéutica y el uso riguroso de la medicina traslacional y biomarcación para la selección de pacientes en la práctica clínica diaria.Preguntas realizadas durante el episodio:¿Cuál es el impacto de la diversificación de blancos terapéuticos y el reto de la secuenciación de los ADCs en el cáncer de ovario?¿Qué implican los datos a largo plazo de los estudios RUBY y GY018 respecto al potencial curativo de la inmunoterapia en cáncer de endometrio?¿Cómo modificará la introducción de ADC dirigidos contra Trop-2 y Nectina-4 el algoritmo de tratamiento actual en el cáncer cervicouterino recurrente o metastásico?Ante la multiplicidad de nuevos mecanismos de acción, ¿cuál será el rol determinante de la biomarcación para optimizar la toma de decisiones clínicas?Referencia:Este contenido se basa en la interpretación crítica de la evidencia científica disponible, así como en la experiencia clínica del o los ponentes como profesionales de la salud en instituciones de referencia.Para profundizar en los conceptos discutidos, se recomienda al profesional de la salud consultar literatura científica vigente, guías clínicas internacionales y la normatividad aplicable en su país.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The first quarter of 2026 has brought a wave of significant changes and advancements in the industry, marked by crucial regulatory updates, strategic acquisitions, and shifts in the competitive landscape. A pressing issue for many companies is the looming patent cliff for several branded biologics. This situation presents both challenges and opportunities for biosimilars in the U.S. market. The introduction of biosimilars for major products like AbbVie's Humira, Johnson & Johnson's Stelara, and Regeneron/Bayer's Eylea is shifting the narrative from slow adoption to a more competitive biosimilar market landscape. Vertex Pharmaceuticals has achieved a milestone with the FDA expanding the label for its gene therapy Casgevy, now approved for treating children as young as two with sickle cell disease or transfusion-dependent beta thalassemia. This expansion emphasizes the potential of gene therapies to revolutionize treatment options for younger patients suffering from these conditions. In a pivotal development, Novartis announced a significant acquisition of UK biotech Myricx. With an upfront payment of $1.1 billion and potential total value up to $1.5 billion, this acquisition is set to enhance Novartis' antibody-drug conjugate (ADC) pipeline by incorporating Myricx's novel payload technology and NMT inhibitor payloads. This move reflects Novartis' focus on precision oncology by improving ADC efficacy through targeting critical enzymatic pathways involved in tumorigenesis. Amgen faced a setback with a voluntary recall of approximately one million bottles of its heart medication Corlanor due to potential contamination, highlighting the critical importance of maintaining rigorous manufacturing quality control to ensure drug safety. The regulatory landscape continues to evolve, illustrated by Robert F. Kennedy Jr.'s Department of Health and Human Services revoking lingering COVID-19 emergency authorizations. This signals a transition towards post-pandemic normalcy and an evolving focus on pandemic preparedness frameworks. Sanofi's Genzyme unit in Ireland faced criticism after an FDA inspection linked to Altuviiio resulted in a Form 483 notice. This incident underscores ongoing challenges in maintaining compliance with stringent regulatory standards and emphasizes the importance of robust quality assurance mechanisms. Lonza is expanding its capacity for producing ADCs and enhancing its partnership with a large U.S. drugmaker, aligning with industry trends toward outsourcing complex biologics manufacturing amid growing demand for ADCs. Genentech is undergoing restructuring, resulting in 103 layoffs as part of a strategic rethink of its early development group. Despite these changes, Genentech entered a $490 million collaboration focused on breast cancer, demonstrating its commitment to innovation amid organizational shifts. AstraZeneca continued its collaborative efforts by signing a $1.7 billion kidney drug discovery pact with Chinese biotech CSPC Pharmaceutical. This partnership emphasizes AstraZeneca's strategy to leverage global collaborations to accelerate drug discovery and development efforts. Scribe Therapeutics filed for an Initial Public Offering (IPO) to advance its CRISPR-based gene editing technologies targeting cardiovascular diseases at a genetic level, highlighting an ongoing shift toward personalized medicine. Celea Therapeutics raised $180 million in venture funding to advance Deupirfenidone into late-stage clinical trials for Idiopathic Pulmonary Fibrosis (IPF), signaling confidence in its therapeutic potential amid ongoing investment trends targeting rare diseases. The Medicines and Healthcare products Regulatory Agency expanded approval for Novo Nordisk's Wegovy for Metabolic-Associated Steatohepatitis with moderate-to-advanced liver fibrosis. This expansion represents significant progress given MASH's rising prevalence and progression risks. BridgeBio's ATTRibute-CM study yielded promising results with Acoramidis offering kidney-protective benefits in transthyretin amyloidosis cardiomyopathy patients—a potential new approach managing this rare disease. Revolution Medicines reported encouraging data for its KRAS inhibitor Zoldonrasib in combination therapies targeting metastatic pancreatic ductal adenocarcinoma—offering new strategies against aggressive cancer types. Brii Bio's phase 2b trial results show promise for a combination therapy aimed at achieving a functional cure for chronic Hepatitis B Virus infection—offering hope for millions affected by this condition. Robust fundraising activities continue within biotech sectors as Monash University and Atisama Therapeutics secure funding from MRFF grants developing therapies targeting chronic lung diseases. Overall, these developments highlight dynamic transformations reshaping therapeutic landscapes through precision medicine approaches leveraging cutting-edge technologies promising improved patient care across various domains within pharmaceutical industries globally.Support the show

Editor-in-Chief of the Archives of Disease in Childhood, Dr Nick Brown, and Senior Editor of ADC, Dr Rachel Agbeko, bring you the monthly Atoms - the highlights of the July 2026 issue. Read it on the Archives of Disease in Childhood website: https://adc.bmj.com/content/111/7/i  Please listen to our regular podcasts and subscribe in Apple Podcasts, Google Podcasts, Stitcher and Spotify to get episodes automatically downloaded to your phone and computer. And if you enjoy the podcast, please leave us a review at https://podcasts.apple.com/gb/podcast/adc-podcast/id333278832 

Achicharradas, sofocadas, torrefactas encaramos el penúltimo ADC de la temporada. Por si no lo habíais notado, el calor ya no es calor, es el síntoma de que hemos entrado en el Termoceno, como nos explica el listísimo Tomás Criado. Hablamos de noches tórridas, de casas de verano, de películas sudorosas, y declaramos (perdón) inaugurado el Dead Girl Summer: el verano de la muerta en vida.  Episodio en colaboración con Filmin. Links artículos. SOBRE EL DEAD GIRL SUMMER: Jessica DeFino hablando sobre cómo los cadáveres están fomentando la industria de los inyectables Investigación de ‘The Guardian' sobre productos de belleza hechos con sentenciados a muerte en China  Ofèlia Carbonell en Substack sobre lo gótico y lo emo y el verano vampiras con las persianas bajadas  LIBRO: Sudor. Mariela Sancari (Comisura, 2026) Otros: Un bolero lumpen: la figura de Pedro Lemebel se resignifica y crece una década después de su muerte. Begoña Gómez Urzaiz, La Vanguardia “Las ciudades no se salvarán solo plantando árboles. Necesitamos un Ministerio del calor”. Noelia Ramírez entrevista a Tomás Criado, El País

As political parties prepare for the 2027 general election, unity may prove just as important as popularity.But a fresh Appeal Court ruling involving the African Democratic Congress (ADC) has raised questions about the party's internal leadership and what lies ahead.Today on Nigeria Daily, we ask: What does the Appeal Court ruling really mean for the ADC?I am Luqman Awwal Agono. My guests are Bolaji Abdullahi, National Publicity Secretary of the African Democratic Congress (ADC); Paul Ibe, spokesperson to former Vice President Atiku Abubakar; and Mr. David West, political analyst.

In today's episode, we spoke with David O'Malley, MD. Dr O'Malley is a professor in the Department of Obstetrics and Gynecology at The Ohio State University College of Medicine and the director of the Division of Gynecologic Oncology at The Ohio State University Comprehensive Cancer Center–James in Columbus, Ohio. In our exclusive interview, Dr O'Malley discussed his approach to treatment selection and sequencing in platinum-resistant ovarian cancer, a disease setting he described as representing the highest unmet need in the field. He emphasized the central role of clinical trial enrollment and biomarker-driven decision-making, alongside practical patient-centered considerations, such as infusion schedule and quality of life.He highlighted the growing importance of antibody-drug conjugates (ADCs) in this setting, noting that folate receptor alpha and HER2 are the two biomarkers most relevant to current practice. Dr O'Malley outlined how National Comprehensive Cancer Network guidelines support treatment across a broader range of expression levels than initial approvals reflected, citing emerging data suggesting activity even at lower expression thresholds. He also addressed payload sequencing, explaining that outside of a clinical trial, he currently uses topoisomerase I–based ADCs and antimicrotubule-based ADCs each one time only, and remains open to targeting the same antigen again if the payload differs.The discussion also touched on combination strategies, resistance biology, and the evolving role of immunotherapy following the survival benefit observed with pembrolizumab (Keytruda) in the phase 3 KEYNOTE-B96 trial (NCT05116189). Dr O'Malley expressed enthusiasm for next-generation payloads, dual-target approaches, and the potential for bispecific antibodies and novel DNA damage response–targeting agents to define the post-ADC treatment landscape.Finally, Dr O'Malley underscored the need for more tumor biopsies to better characterize resistance mechanisms and called for expanded pharmaceutical investment in retreatment and cross-resistance studies to guide future sequencing decisions.

The opposition says it is determined to unseat the ruling APC in 2027. But can it achieve that if one of the platforms expected to play a major role is caught in a legal battle?A recent court ruling has thrown the future of the NDC into uncertainty, prompting questions about what happens if the party eventually loses its registration. Would that derail Peter Obi's political ambitions? Would it affect ongoing talks among opposition figures? Or is this simply another legal hurdle that can be overcome?In this episode of Nigeria Daily, we examine what the court's decision really means, what the opposition is saying, and whether Nigeria's political landscape could change before the next general election.

The Tim Conway Jr. Show Hour 2 (6.25) This hour goes from hope to havoc. We kick off with a real breast cancer breakthrough — the FDA just greenlit Trodelvy as a first-line treatment for the hardest-to-treat triple-negative breast cancer, the first ADC approved across PD-L1 status, and it's already proving more durable than chemo. Then sports get ugly: the WNBA suspended Phoenix's Alyssa Thomas and slapped her with a flagrant 2 for driving her fist into Caitlin Clark's throat — a hit refs somehow missed live. Next, the House Whisperer himself, Dean Sharp, breaks down home electrical do's and don'ts (electricity isn't magic, it's water in a pipe) and the man-stuff guide to buying power tools. And we close on the stench story gripping LA: 85 million pounds of spoiled meat, seafood, and bread rotting inside a burned-out Boyle Heights warehouse, as crews race to haul it out before it becomes a full-blown biohazard. Breakthroughs, cheap shots, and a biohazard. Hit play. breakthrough, game-changer, greenlit, FDA-approved, cheap shot, flagrant, dropped the hammer, no-call, caught on camera, ugly, stench, biohazard, rotting, race against time, hauled out, do's and don'ts, man stuff, must-know, dangerous, exposed, accountability, fallout, sidelined, suspended, slammed, viral, jaw-dropping, hope vs. havoc, the truth about, what you need to know. See omnystudio.com/listener for privacy information.

Keith, Terry, and Jill discussed recent activities. Keith shared details about attending a local festival in Livingston, Illinois featuring a pink elephant statue, where they saw a beauty pageant and discussed potentially involving Andrea in an upcoming Miss UFO pageant. The conversation also touched on family activities, including Jill’s camping trip with four grandchildren and Keith’s church fishing outing. Keith shared updates about his weekend activities, including Robin buying dirt boxes with treasures for three children and plans to register for a Miss UFO event. The group discussed their new Amazon storefront, which is still being developed and populated with relevant products. Support our podcast by shopping at our Amazon marketplace page:see what selling fast on Amazon! News of the Week Terry then shared a news story about an overturned semi-truck in Texas containing an estimated 2 million bees from Queen Bee Supply Company, which required local residents to stay indoors while the bees were rounded up and transported to a honey farm. Jill shared about Jonathan, a 194-year-old turtle living on Saint Helena island, while Terry presented stories about German man Tommy Schmidt’s record-breaking 65,000 Lego brick bratwurst sculpture and an Oklahoma family’s surprise when their dog brought an armadillo into their home. Keith then described a story about a month-old pony named Mile who moved into an apartment in Croatia after being rejected by his mother, requiring round-the-clock care and eventually gaining weight and appearing cheerful. Terry shared two news items: a truck fire in Tennessee caused an impromptu fireworks display on Interstate 75 near Chattanooga, and a police department in Washington discovered a bird nest with four eggs in a motorcycle’s engine compartment, which they named “Traffic Birdie.” Jill's Weird Words The group then played a game of “weird words,” where Jill presented definitions and participants guessed meanings, covering terms like Freudian, manifold, woodshed, pan dowdy, coloratura, prolix, ADC (adze), and recondite. As the group discussed word meanings and etymologies, Jill explained terms like “firth” as a narrow sea inlet and “toodle” meaning to travel leisurely. Terry's Top 10 List Terry shared a humorous top ten list about reasons someone might need a CAT scan, which included jokes about cats acting as radiologists and other playful scenarios. Anchor Topic The segment of the show where we discuss blindness related topics. On the schedule is low vision, but we decide to return to living skills.Keith leads the focus on daily self-care activities like getting dressed and bathing while emphasizing the importance of independence. The group discussed strategies for blind individuals to identify bathroom products, including using rubber bands to mark bottles, organizing them on different shelves, and reading labels before showering. Keith and Terry shared personal experiences with accessibility challenges in bathrooms, including issues with children moving products and the benefits of pump bottles secured to shower walls. Email and Final Thoughts Keith presents an email from a listener in Florida who runs an alligator farm. He follows it by a touching story about a woman, a mother of three, who practice the principle of “pay it forward,” when she helped out another young mother years later. There are also two voicemails that are shared. The first from a young farmboy with an overturned wagon. The next one contains some food for thought that ponders the issue of evil. As usual, we wrap it all up with our final thoughts. The final word from our AI companion The meeting was a recording session for a comedy show where Keith, Jill, and Terry shared various content including email submissions, voicemails, and their own jokes. Keith read several email submissions including stories about a rattlesnake farm visit and an anonymous act of kindness at a mechanic’s shop. The team discussed a news story about singer Olivia Rodrigo’s comments about concertgoers wearing adult diapers for prime seating positions, and shared philosophical content about evil and its existence. The session concluded with the team taking turns sharing final thoughts and jokes before signing off. Show notes written by AI, edited as needed by Keith. Sponsored by: Retro Radio Podcast. Bringing you family-friendly entertainment through classic, old-time radio. Episodes are posted daily. Keith and his Retrobots share everything in his collection from the days of vintage radio. Adventure, comedy, detective, westerns, and lots in between. If you don't hear your favorite show, just ask Visit the web page today, https://retro-otr.com

¿Te sientes segure? Vuelve Marcos Bartolomé y sus Relaciones Internacionales para analizar cómo se regulan nuestros rincones de libertad (controlada): los espacios seguros. Rastreamos desde su origen corporativo y activista a las contradicciones que generan en la actualidad. Plus: Bego saca un expediente Urzaiz que urgía traer a la mesa de ADC. Episodio en colaboración con Filmin. Links libros y artículos mencionados:  ‘Intimidades congeladas: las emociones del capitalismo'. Por Eva Illouz. ‘Mapping Gay L.A. The Intersection of Place and Politics'. Moira Rachel Kenney ‘The Case for Safe Spaces', de Anne-Laure White  ‘Stone Butch Blues', de Leslie Feinberg. Traducido por Layla Martínez Vicente (Levanta Fuego, 2021). Atiende amiga:  Marcos: Analog Africa Noelia: Película Backrooms/ Ensayo Estéticas liminales Begoña: Fun Home, Entre amics (castellano), La vida imaginada

Doing stuff is easy, not doing stuff is hard, particularly if you've been doing it for a year. This isn't just about smoking, drinking, and wild banjo playing on the porch at midnight, though we talk about it on the podcast (https://adc.bmj.com/content/111/5/457.2), but also echoed in an upcoming Editorial (https://adc.bmj.com/content/early/2026/04/03/archdischild-2026-330309). If reality were alterable by waving your hand, do you think you might do it? If you're intrigued, the work on X-rays for PICC-tips might enthrall you (https://adc.bmj.com/content/111/5/457.1) or just wave at people. See what happens. (Note, the ADC is not responsible for any adverse events if you do this in London rather than the North!). This podcast is written and presented by Prof Bob Phillips (Hull-York Medical School, UK), Archimedes section editor of Archives of Disease in Childhood. He brings you the monthly episode about evidence-based medicine for paediatricians. We would love for you to be involved in Archi [https://adc.bmj.com/pages/authors#archimedes]. Just ask the questions that your patients are offering you - and tell us how you're finding the podcast offerings. Please listen to our regular podcasts and subscribe in your preferred platform to get episodes automatically downloaded to your phone and computer. And if you enjoy the ADC Podcast, please leave us a review at https://podcasts.apple.com/gb/podcast/adc-podcast/id333278832.

 The Ekiti State governorship election has been concluded, with incumbent governor Biodun Abayomi Oyebanji of the APC securing another four-year mandate after defeating candidates of the PDP, ADC, and other political parties.But even as celebrations begin, questions remain over whether the opposition will accept the outcome and whether allegations of vote-buying and electoral irregularities could end up in court. Join us in this episode of Nigeria Daily as we examine the reactions from the major political parties and what the Ekiti election could mean for the 2027 general elections. 

En este episodio del pódcast BreastLink de ScienceLink, el Dr. Juan Carlos Samamé conduce una revisión académica sobre los hallazgos más relevantes presentados en el congreso anual de cáncer de mama de la Sociedad Europea de Oncología Médica, en compañía del Dr. Denis Landaverde, Jefe de Oncología Médica del Hospital México en San José, Costa Rica. La conversación inicial se enfoca en la enfermedad luminal (HR+/HER2-). Se aborda el ensayo PREcoopERA, diseñado para evaluar la eficacia y seguridad de giredestrant con el objetivo de determinar si puede sustituir los tratamientos hormonales tradicionales en mujeres premenopáusicas con cáncer de mama temprano; el estudio evERA, centrando la discusión en los desenlaces reportados por los pacientes ante la combinación de giredestrant y everolimus; y la actualización del estudio CAPItello-291, que investiga el uso de capivasertib junto a fulvestrant tras la progresión a inhibidores de CDK4/6.Posteriormente, el debate transita hacia el cáncer de mama triple negativo y la enfermedad HER2 positiva. Se explora el papel de datopotamab deruxtecan en el entorno triple negativo analizado en el estudio TROPION-Breast02. En el escenario HER2 positivo temprano, se discuten las estrategias de desescalamiento terapéutico y la posible omisión de quimioterapia evaluada en el ensayo PHERGain. La sesión concluye analizando el uso de trastuzumab deruxtecan en la neoadyuvancia bajo el estudio DESTINY-Breast11, así como el reto de secuenciar múltiples ADC en la enfermedad avanzada.Preguntas realizadas durante el episodio:¿Es seguro omitir los análogos de LHRH al usar giredestrant en enfermedad luminal temprana?¿Cómo impacta datopotamab deruxtecan en la calidad de vida de pacientes con cáncer de mama triple negativo metastásico?¿Es eficaz secuenciar un segundo ADC tras la progresión a trastuzumab deruxtecan en la enfermedad HER2+ avanzada?¿Pueden las imágenes (PET-CT o RM) guiar de forma segura la omisión de quimioterapia en tumores HER2+ temprano?Referencia:Este contenido se basa en la interpretación crítica de la evidencia científica disponible, así como en la experiencia clínica del o los ponentes como profesionales de la salud en instituciones de referencia.Para profundizar en los conceptos discutidos, se recomienda al profesional de la salud consultar literatura científica vigente, guías clínicas internacionales y la normatividad aplicable en su país.Material exclusivo para profesionales de la salud. Este material ha sido desarrollado únicamente con fines educativos e informativos y no tiene la intención de sustituir el juicio clínico de los profesionales de la salud. Las opiniones y declaraciones presentadas en este contenido son responsabilidad exclusiva de los ponentes y no reflejan necesariamente la postura institucional de ScienceLink ni de terceros mencionados. La información presentada se basa en el conocimiento y la experiencia profesional de los ponentes. La veracidad, exactitud y actualidad científica de los datos son de su exclusiva responsabilidad. Así mismo garantizan que el contenido utilizado no infringe derechos de autor de terceros y asumen toda responsabilidad por su uso.

Timestamps0:00 Intro 1:06 Welcome Aux 2:31 LCK recap from First Stand 9:16 HLE in spring 20:28 HLE player by player 41:48 The ideal ADC style 49:47 T1 56:12 Peyz on T1 1:06:50 Aux MSI predictions 1:13:37 Welcome Emily -- TES 1:34:14 WE what did they do 1:44:00 Knight and BLG 1:57:50 Emily MSI predictions

For years, political defections have remained a recurring feature of Nigeria's democratic journey, with politicians frequently moving from one party to another after winning elections.Now, the National Democratic Congress, NDC, has introduced a policy requiring all candidates seeking elective offices on its platform to sign anti-defection affidavits and indemnity forms, committing themselves to vacate their seats if they leave the party after winning elections.The move has sparked fresh debate about political loyalty, party discipline and whether elected officials should be allowed to retain their mandates after defecting from the parties on which they were elected.Join us in this episode of Nigeria Daily as we examine why the NDC introduced the policy, what it hopes to achieve, and whether anti-defection affidavits can help strengthen Nigeria's democracy ahead of the 2027 elections.

For years, political parties have served as the platforms through which politicians seek power, build alliances, and contest elections in Nigeria.Now, a Federal High Court ruling directing INEC to deregister the African Democratic Congress (ADC) and four other political parties has sparked fresh debate about the future of opposition politics and democratic competition ahead of the 2027 general elections.Join us in this episode of Nigeria Daily as we examine what the ruling means for the ADC, the politicians aligned with the party, including former Vice President Atiku Abubakar, and the future of Nigeria's political landscape.

Tanya Dorff joins Tom and Brian to discuss her ASCO 2026 data on a novel dual targeting ADC in prostate cancer. The broader scope of ADC development in prostate cancer is discussed with a focus on cytopenia toxicity and future direcctions.

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:https://www.mycme.com/courses/the-evolving-role-of-antibody-drug-conjugates-in-metastatic-triple-negative-breast-cancer-10800SummaryThis CME/CE-certified podcast will provide multidisciplinary clinicians with an evidence-based update on the evolving role of TROP2-directed antibody-drug conjugates (ADCs) in the frontline treatment of metastatic triple-negative breast cancer. A medical and an ocular oncology specialist review the latest efficacy and safety data from pivotal clinical trials evaluating ADCs, their integration into contemporary treatment algorithms, and guideline recommendations based on PD-L1 status, BRCA mutation status, and immunotherapy eligibility. Learners will explore key factors influencing treatment selection, compare the benefits and limitations of more established therapeutic options, and examine practical strategies for preventing, recognizing, and managing ADC-associated toxicities. Special emphasis will be placed on multidisciplinary approaches to the management of ocular adverse events and other clinically significant toxicities to optimize patient outcomes and support safe implementation of these therapies in clinical practice.Learning ObjectivesEvaluate the current and emerging clinical evidence surrounding the use of trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugates (ADCs) in the first-line treatment of metastatic triple-negative breast cancer (TNBC)Integrate TROP2-directed ADCs into frontline treatment regimens for metastatic TNBC based on the latest clinical evidence, guidelines, and patient- and tumor-specific factorsApply multidisciplinary and patient-centric strategies for the prevention, recognition, and management of toxicities associated with the use of TROP2-directed ADCs in patients with metastatic TNBCThis activity is accredited for CME/CE CreditThe National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.The National Association for Continuing Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.The National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.50 contact hours (which includes 0.50 hours of pharmacology). For additional information about the accreditation of this program, please contact NACE at info@naceonline.com.Faculty and Moderator Aditya Bardia, MDProgram Director, Breast Medical Oncology, UCLAProfessor of Medicine, UCLALos Angeles, CADr. Bardia has disclosed the following financial relationships:Consultant: Alyssum, AstraZeneca/Daiichi, BMS, Eli Lilly, Genentech, Gilead, Menarini, Merck, Novartis, Pfizer, VyomeAdvisor/Advisory Board: Alyssum, AstraZeneca/Daiichi, Eli Lilly, Genentech, Gilead, Menarini, Merck, Novartis, Pfizer, VyomeContracted Research: AstraZeneca/Daiichi, Eli Lilly, Genentech, Gilead, Menarini, Merck, Novartis, PfizerStock options: Vyome (immuno-inflammatory and rare diseases)All of his consultant, advisor/advisory board, and contracted research disclosures are related to cancer.Maura Di Nicola, MDAssistant Professor of OphthalmologyBascom Palmer Eye InstituteMedical Director of Imaging and EchographyBascom Palmer Eye InstituteMiami, FLDr. Di Nicola has disclosed the following financial relationships:Consultant: AbbVie (ophthalmology), SpringWorks Therapeutics (oncology)Advisor/Advisory Board: AbbVie (ophthalmology)Research Grant: Castle Biosciences (ocular oncology)Please review additional planner disclosures here.Disclosure of Commercial SupportThis educational activity is supported by a medical education grant from AstraZeneca Pharmaceuticals and a medical education grant from Daiichi Sankyo, Inc.Please visit  http://naceonline.com to engage in more live and on demand CME/CE content.

The proposal for a single six-year presidential term in Nigeria is once again dominating national conversations, sparking heated debate across political circles, governance experts, and social media platforms.At the heart of the discussion is a major question: Should Nigeria consider a six-year single term presidency as part of constitutional reform, or is it a dangerous shift that could weaken democratic accountability?The idea, which has resurfaced amid ongoing Nigeria constitutional amendment debates, touches on key issues such as electoral reform in Nigeria, presidential tenure limits, governance stability, and democratic accountability in Africa's largest democracy.Supporters say a single-term presidency in Nigeria could reduce the pressure of re-election politics, lower election costs, and allow leaders to focus fully on governance. Critics, however, warn it could reduce voter power, weaken checks and balances, and reshape Nigeria's democratic structure in ways that may not serve public interest.And so today on Nigeria Daily, we ask the big question trending across Nigerian politics, 2026 political news, constitutional reform Nigeria, and election reform discussions:

In this episode of the Mic On Podcast, Seun Okinbaloye sits with Solomon Dalung, former Minister of Youth and Sports Development and legal practitioner, who shares his views on coalition politics, governance, and the 2027 elections.Dalung discusses the challenges facing the ADC coalition, criticizes recent political realignments, and argues that growing insecurity and public dissatisfaction have weakened confidence in the current administration. He also reflects on his role in the formation of the APC, expressing disappointment with the party's performance in government.Looking ahead to 2027, Dalung urges Nigerians to prioritize competence over party loyalty and remain actively engaged in the electoral process, describing the next election as a defining moment for the country's future.Guest:Solomon Dalung(Former Minister of Youth and Sports Development / Legal Practitioner)

Across Nigeria's political landscape, party primaries are often described as the foundation of democracy within political parties. They determine who gets the ticket, who flies the party's flag, and ultimately who appears before voters on election day.But what happens when influential politicians lose those primaries? Should party leaders step in to help them find a way back, or should the verdict of delegates remain final?Recent developments within the APC have sparked fresh debate about the sanctity of party primaries, the powers of party leadership, and the future of internal democracy in Nigeria.Today on Nigeria Daily, we ask: When party primaries speak, should political leaders intervene?

Toxicities related to antibody-drug conjugates (ADCs) can significantly impact quality of life for patients with locally advanced or metastatic bladder cancer, but data-driven programs can help multidisciplinary teams manage some of the most challenging adverse events. In this episode, CANCER BUZZ speaks with Cindy Y. Jiang, MD, assistant professor at MD Anderson Cancer Center, about how her institution conducted and implemented research to aid management of rashes and peripheral neuropathy associated with the ADC enfortumab vedotin combined with pembrolizumab. Guest:  Cindy Y. Jiang, MD Assistant Professor Department of GU Medical Oncology MD Anderson Cancer Center Houston, TX "It's important to assemble this team before you start on any sort of journey, because as oncologists, we're definitely not experts in skin rashes or neurological issues, and so you really need to rely heavily on those collaborators." — Cindy Y. Jiang, MD Resources: Bladder Cancer Antibody-Drug Conjugates

This episode of the PeerDirect Medical News Podcast examines the rapidly expanding Ebola outbreak in Congo and concerns over weakening global public health infrastructure, reviews new Phase III obesity data showing substantial weight loss with Lilly's triple-agonist retatrutide, and highlights promising ASCO 2026 lung cancer data for a TROP2-directed ADC combined with pembrolizumab in frontline NSCLC.

In Nigeria's political space, internal party disputes are not new. But when those disputes move from party offices into the electoral arena, they raise far more serious questions.The Peoples Democratic Party, one of the country's biggest opposition platforms, is once again at the centre of such uncertainty. Competing factions within the party continue to lay claim to authority, raising concerns about who truly represents the PDP structure.But beyond the leadership struggle lies a more complex scenario what happens if rival factions of the same party go beyond disagreement and present separate candidates in an election?At that point, the issue is no longer just about party unity. It becomes a question of legality, recognition, and ultimately, where votes will go on election day.So today on Nigeria Daily, we examine the unfolding situation within the PDP, speak with a Daily Trust correspondent following the crisis closely, hear from a lawyer on the legal implications, and later, a political analyst helps us understand what this could mean for Nigeria's opposition politics going forward.

This episode featured @nigeriasbest and @phoenix_agenda They discussed:2027 General Election Primaries with a focus on ADC and NDC

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we'll explore a landscape teeming with strategic partnerships, groundbreaking clinical trial results, regulatory shifts, and innovative therapeutic approaches that are redefining patient care and drug development. Pfizer's monumental $10 billion collaboration with Innovent Biologics stands out as a testament to the shifting dynamics of the oncology sector. This partnership aims to develop 12 antibody-drug conjugate (ADC) and multispecific antibody programs, spotlighting these therapies' growing significance in oncology. The precision of antibodies in delivering cytotoxic agents directly to cancer cells offers a new frontier in minimizing collateral damage to healthy tissues—a crucial advancement in cancer treatment. The deal not only highlights Pfizer's commitment to expanding its oncology pipeline but also underscores the strategic importance of leveraging China's accelerated drug development ecosystem. In regulatory news, AstraZeneca's Imfinzi has garnered FDA approval for BCG-naive high-risk non-muscle-invasive bladder cancer. This milestone for PD-L1 inhibitors reflects the evolving landscape of immunotherapy. By harnessing monoclonal antibodies in combination therapies, the potential for enhanced anticancer efficacy is significant. With few therapeutic alternatives available, this approval presents a lifeline for many bladder cancer patients. Clinical trial outcomes also continue to capture attention. Eli Lilly's Nectin-4 targeting ADC showed promising results in advanced urothelial cancer, positioning itself as a potential competitor to Padcev. This innovation in ADC technology demonstrates the industry's relentless pursuit of targeted therapies that can revolutionize treatment paradigms. Bristol Myers Squibb's mezigdomide offers another example by showing a 52% reduction in progression risk for relapsed or refractory multiple myeloma patients, emphasizing the focus on addressing specific molecular pathways. In the realm of bispecific antibodies, Phanes Therapeutics' CLDN18.2/CD47 targeting therapy reported encouraging Phase 2 results in metastatic pancreatic ductal adenocarcinoma. These antibodies' ability to simultaneously engage multiple targets enhances their therapeutic efficacy against stubborn cancers, broadening the horizon for treatment possibilities. Meanwhile, Replimune's resubmission of its RP1 melanoma Biologics License Application (BLA) highlights the intricate dance between drug development and regulatory processes amid organizational shifts at the FDA. Such efforts reflect the continual adaptation required within the industry to navigate complex regulatory landscapes. On the funding front, Psilera's successful $8.8 million seed round indicates growing interest in psychedelic therapies for neurological conditions. Similarly, Reprogram Biosciences raised $6 million for its AI-driven cell reprogramming oncology platform, illustrating how artificial intelligence is becoming integral to advancing drug discovery and development. However, not all updates were positive. Agios Pharmaceuticals faced setbacks as their pyruvate kinase activator failed a Phase 2b trial for lower-risk myelodysplastic syndromes, serving as a sobering reminder of the inherent risks involved in drug development. Dizal Pharma emerges as a beacon of hope in lung cancer treatment following Takeda's EGFR exon 20 drug setback. By challenging existing treatments with promising small molecule data, Dizal exemplifies precision medicine's role in redefining oncology protocols—offering personalized patient options that could set new standards in treatment efficacy. The issue of drug pricing remains contentious, particularly highlighted by an AARP analysis showing an 81% increase post-launch prices stateside compared to a 13% decrease abroad. This disparity raises critical questions about achieving equitable access across markets amid Medicare negotiations and global pricing strategies like "most favored nation" policies. Regulatory updates continue with Johnson & Johnson's Tremfya label expansion stateside and AbbVie's EU extension for Venclyxto—moves that reflect efforts to maximize therapeutic reach and commercial viability across diverse geographies. Finally, Gilead Sciences' decision to discontinue its lead rheumatoid arthritis drug from MiroBio underscores ongoing challenges within emerging fields like BTLA agonists—a reminder of both innovation's promise and its perilous nature when faced with unproven therapeutic avenues. As these varied developments unfold, they collectively signal an era characterized by rapid scientific innovation and strategic collaborations across geographies alongside evolving regulatory landscapes—all driving towards enhanced patient care through more effective treatments globally. This concludes today's insights from Pharma Daily—a world where dynamic change continues reshaping healthcare delivery standards towards unprecedented possibilities for patient outcomes worldwide. Thank you for joining us; stay tuned for more updates on tomorrow's horizon-shaping advancements.Support the show

CME credits: 0.25 Valid until: 01-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/chairpersons-perspective-her2-in-solid-tumors-from-pathology-to-personalized-treatment-plans/54582/ Dr. Kathleen Moore reviews the clinical significance of HER2 expression across diverse solid tumors and its role in guiding treatment decisions. She outlines HER2 testing methodologies, including immunohistochemistry (IHC), to identify patients with advanced solid tumors who may benefit from HER2-targeted antibody–drug conjugates (ADCs). Dr. Moore summarizes key data from trials such as DESTINY-PanTumor02, DESTINY-Lung01, and DESTINY-CRC02 that supported tumor-agnostic approval of trastuzumab deruxtecan (T-DXd) for previously treated metastatic HER2-positive (IHC 3+) solid tumors, along with strategies for proactive monitoring and management of ADC-associated adverse events.=

Editor-in-Chief of the Archives of Disease in Childhood, Dr Nick Brown, and Senior Editor of ADC, Dr Rachel Agbeko, bring you the monthly Atoms - the highlights of the June 2026 issue. Read it on the Archives of Disease in Childhood website: https://adc.bmj.com/content/111/6/i Please listen to our regular podcasts and subscribe in Apple Podcasts, Google Podcasts, Stitcher and Spotify to get episodes automatically downloaded to your phone and computer. And if you enjoy the podcast, please leave us a review at https://podcasts.apple.com/gb/podcast/adc-podcast/id333278832 

From Discovery to Delivery: Charting Progress in Gynecologic Oncology, hosted by Ursula A. Matulonis, MD, brings expert insights into the most recent breakthroughs, evolving standards, and emerging therapies across gynecologic cancers. Dr Matulonis is chief of the Division of Gynecologic Oncology and the Brock-Wilson Family Chair at the Dana-Farber Cancer Institute, as well as a professor of medicine at Harvard Medical School, both in Boston, Massachusetts.In this episode, Dr Matulonis was joined by Meghan E. Shea, MD, an attending medical oncologist and ambulatory medical director and disease program leader for medical oncology at Beth Israel Deaconess Medical Center in Boston. Together, they explored the current landscape of cervical cancer, from the urgent need for expanded vaccination and screening to the evolving role of immunotherapy and antibody-drug conjugates (ADCs) across disease settings.Dr Shea opened by addressing the epidemiology of cervical cancer, noting that despite decades of progress, rates are now plateauing and rising among women under 50 years of age. She identified 3 interrelated drivers of this trend: declining rates of routine gynecologic screening, inconsistent uptake of human papillomavirus (HPV) vaccination, and persistent high-risk HPV infections, particularly HPV 16 and 18, which are responsible for most cases. The conversation then turned to the effect of immunotherapy on cervical cancer treatment. Dr Shea traced the evolution of pembrolizumab (Keytruda) from its initial 2018 approval as a single agent in recurrent/metastatic disease to its more recent integration into the frontline setting. The phase 3 KEYNOTE-A18 trial (NCT04221945) demonstrated that adding pembrolizumab to standard weekly cisplatin-based chemoradiation significantly improved outcomes for patients with locally advanced disease. Although responses to immunotherapy, when they occur, are often durable, Dr Shea acknowledged that response rates remain lower than anticipated for a virally driven malignancy, underscoring the need for novel combinations and a deeper understanding of resistance mechanisms. Drs Matulonis and Shea both agreed that immunotherapy combined with ADCs represents one of the most compelling directions for the field, with phase 2 data for sacituzumab tirumotecan plus pembrolizumab generating interest ahead of anticipated phase 3 results.On the ADC front, Dr Shea reviewed the 2 agents in this class that are currently FDA-approved for cervical cancer. Tisotumab vedotin-tftv (Tivdak) offers the advantage of biomarker-independent use, though its requirement for ophthalmologic monitoring at every treatment visit creates real-world access challenges outside major academic centers. Trastuzumab deruxtecan-nxki (Enhertu), approved in the HER2 immunohistochemistry 3+ setting based in part on the results of the phase 2 DESTINY-PanTumor02 trial (NCT04482309), has generated robust response rates but is most likely to benefit patients with adenocarcinoma. Dr Shea also highlighted additional targets under investigation, including Trop-2, Nectin-4, and B7-H4, with multiple phase 3 trials ongoing in both the frontline and recurrent settings.The discussion closed with a look at the locally advanced disease landscape, where the NRG Oncology cooperative group is conducting a phase 3 trial to evaluate whether integrating the neoadjuvant carboplatin/paclitaxel regimen from the INTERLACE trial (NCT01566240) with the pembrolizumab-based regimen from KEYNOTE-A18 can further improve outcomes and reduce the morbidity associated with brachytherapy. Dr Shea expressed optimism about this question, citing preliminary experience suggesting that neoadjuvant chemotherapy may reduce the need for invasive radiation techniques.

Welcome back to the Oncology Brothers podcast! In this episode, we were joined by Dr. Erika Hamilton from the Sarah Cannon Cancer Research Institute to discuss the latest advancements in breast cancer treatment following ESMO Breast 2026. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media: X/Twitter: https://twitter.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ We dived into key studies and recent FDA approvals, including: The exciting approval of Vepdegestrant from the VERITAC-2 study for ESR1-mutated breast cancer. The importance of ovarian function suppression in premenopausal patients, even with the advent of oral SERDs. Updates on HER2-positive disease treatments, including the newly approved T-DXd in neoadjuvant settings and the implications of de-escalation strategies. Insights from the SATEEN and BRE-354 studies on the use of antibody-drug conjugates (ADCs) after previous ADC treatments. A look at the Dato-DXd and Sacituzumab in frontline triple-negative breast cancer and how to choose between them. Join us as we unpack these critical findings and their implications for clinical practice. Don't forget to check out our other episodes for more treatment algorithms and conference highlights. Stay tuned for ASCO 2026, and remember, we are the Oncology Brothers! #ESMO2026, #ESR1mutation, #BreastCancerResearch, #PrecisionMedicine, #OncologyBrothers

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of noteworthy advancements and challenges that are shifting the landscape of drug development and patient care. Starting with AstraZeneca and Daiichi Sankyo, their Trop2-directed antibody-drug conjugate, Datroway, has secured FDA approval for first-line treatment in triple-negative breast cancer. This form of cancer is notoriously aggressive and offers limited treatment options, making this approval a significant milestone. It positions Datroway as a key player in the ADC market targeting TNBC, highlighting the increasing role of antibody-drug conjugates in oncology. This advancement not only expands therapeutic options for patients but also emphasizes the growing importance of ADCs in effectively targeting cancer cells while sparing healthy tissues. In another exciting development, Merck and Kelun Biotech have reported on their SAC-TMT ADC, which when paired with Keytruda, shows a profound impact on PD-L1-positive non-small cell lung cancer patients. Their combination therapy demonstrated a remarkable 65% reduction in disease progression or death compared to Keytruda alone. Presented at the ASCO annual meeting, these findings could potentially revolutionize first-line treatments for NSCLC, further underscoring the promising therapeutic potential of combining ADCs with immunotherapies. However, AstraZeneca faced a setback with a novel breast cancer drug as an FDA advisory committee recommended against its approval. Interestingly, the European Medicines Agency provided a favorable opinion, illustrating the divergent regulatory landscapes across continents. Such discrepancies highlight the complex regulatory environment pharmaceutical companies must navigate and could influence strategic decisions regarding market focus. On the legal front, Eli Lilly is embroiled in controversy over an alleged $200 million rebate fraud scheme involving its diabetes drug, Trulicity. This situation sheds light on ongoing issues within pharmaceutical distribution channels and raises questions about compliance and oversight mechanisms necessary to prevent such financial misconduct. Meanwhile, industry dynamics continue to evolve as AbbVie announced workforce reductions in its Allergan Aesthetics unit. This move reflects broader trends where companies streamline operations to prioritize core competencies and promising therapeutic areas. From a regulatory perspective, Maat Pharma's decision to seek re-examination for its graft-versus-host disease medication underscores the iterative nature of drug approval processes. Persistence in addressing regulatory feedback remains crucial as companies strive for successful market entry. In obesity management, Novo Nordisk's oral GLP-1 receptor agonist, Wegovy, gains traction as a convenient treatment option. The shift towards oral medications could significantly improve patient adherence and outcomes by offering an easier alternative to injections. Biogen's decision to terminate its collaboration with Denali Therapeutics after unsuccessful phase 2 trials for a Parkinson's disease candidate highlights the inherent risks in neurological drug development. Rigorous clinical evaluation remains essential to ensure efficacy before advancing therapies further. Despite these advancements, challenges persist as Biogen and Denali's BIIB122 failed in phase 2b trials for idiopathic Parkinson's disease. This underscores the complexity of neurological disorders and emphasizes the need for continued innovation targeting LRRK2 kinase inhibitors. In the realm of CAR-T therapies, Novartis' T-Charge platform faces competition from emerging in vivo technologies. This competitive landscape demonstrates rapid evolution within cell therapy domains, aiming to enhance efficacy and accessibility for patients. Meanwhile, strategic mergers and acquisitions continue as Liminatus Pharma acquires CAR-T biotech Innocsai for $320 million, underscoring sustained interest in oncology cell therapies. Switching gears to Eli Lilly's recent Phase 3 TRIUMPH-1 trial results for retatrutide, they reveal promising weight loss outcomes comparable to bariatric surgery. As a triple hormone receptor agonist targeting GLP-1, retatrutide holds significant potential in addressing obesity—a condition with profound public health implications. Medtronic's acquisition of SPR Therapeutics to enhance its chronic pain portfolio reflects a focus on minimally invasive treatments. Financially, Research Alliance III raised $75 million through a SPAC IPO targeting mergers with China-based biotech firms, signaling increased global collaboration within the sector. Dandelion Health's $14 million Series A funding aims to advance clinical intelligence platforms that could transform drug development through data analytics. Finally, Moderna's mRNA-based flu vaccine is set for review by the FDA's vaccine advisory committee after overcoming initial regulatory hurdles. This scrutiny highlights ongoing challenges faced by novel vaccine technologies within rigorous regulatory environments. In summary, these developments illustrate an industry at the forefront of scientific innovation while grappling with regulatory complexities and operational challenges. From antibody-drug conjugates and immunotherapy combinations to gene editing and advanced cell therapies, there's a clear commitment to improving patient outcomes through novel scientific approaches. As these trends evolve, they promise to redefine treatment landscapes across various therapeutic areas—offering new opportunities for scientific advancements and enhanced patient care worldwide.Support the show

Discuto a decisão que o STF deu às ADI's 7612 e 7631 e à ADC n. 92 que tratavam da lei n. 14.611/23. Discuto os fundamentos das ações e as razões pelas quais o STF declarou válida a lei. Falo sobre a conformidade desta lei também com a Convenção n. 100 da OIT e com leis de outros países.

ADC talks Ketel Marte, Ryne Nelson, and his big hit last night.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The industry is currently navigating a pivotal era marked by a blend of scientific innovation, regulatory shifts, and intriguing clinical trial results. A key regulatory upheaval unfolds as the FDA faces leadership changes. The recent departures of key figures from both the Center for Biologics Evaluation and Research (CBER) and the Center for Drug Evaluation and Research (CDER) underscore a period of uncertainty. With former commissioner Marty Makary stepping down, concerns arise about how these changes might affect drug approvals and regulatory guidance at such a crucial time in the industry. Turning to clinical trials, Regeneron has experienced a setback as its lag-3 inhibitor failed to surpass Merck's Keytruda in phase 3 melanoma studies. This marks Regeneron's second significant late-stage failure within a year, prompting analysts to reassess its strategic direction in oncology. In parallel, Regeneron has inked a $2.3 billion agreement with Parabilis Medicines to develop an advanced antibody-drug conjugate (ADC)-like therapy. The goal is to enhance targeting capabilities by improving binding to complex target sites, which could revolutionize ADC technology. Similarly, BioMarin's substantial investment in Inozyme's enzyme replacement therapy faced hurdles after falling short on one of two primary endpoints in a phase 3 trial for a rare genetic disorder. Such outcomes highlight the inherent risks and high stakes involved in late-stage drug development. Yet, innovation continues to drive progress. Vincentage Pharma's oral GLP-1 agonist has demonstrated a promising mean weight loss of 12.4% over a year, positioning it as a competitor to Eli Lilly's Orforglipron in the burgeoning Chinese market. This reflects the global pursuit to harness GLP-1 receptor agonists in tackling metabolic disorders and obesity. Ipsen has made strides with its long-acting neurotoxin for aesthetic applications, advancing into phase 3 trials following encouraging phase 2 results that showed significant improvements in frown lines lasting up to 24 weeks post-treatment. This progress suggests robust competition against established players like Botox. Meanwhile, Merck and Kelun-Biotech have successfully completed a phase 3 trial with their trop2-directed ADC sacituzumab tirumotecan (SAC-TMT) for endometrial cancer, achieving primary endpoints and paving the way for further regulatory submissions. Such advancements emphasize ADC technology's growing importance in oncology therapeutics. Broad industry trends reflect strategic investments, exemplified by Boston Scientific's $1.5 billion investment in Mirus and an option to acquire its transcatheter aortic valve replacement system—highlighting continued interest in high-growth medtech sectors. In another notable development, Daiichi Sankyo and AstraZeneca have reached a milestone with their ADC Enhertu, securing dual FDA approvals for early breast cancer treatment. These approvals underscore Enhertu's potential to expand treatment options for patients at an early disease stage, potentially altering standard treatment protocols. On the regulatory front, AstraZeneca has secured FDA approval for baxdrostat—an aldosterone synthase inhibitor developed through its acquisition of CinCor Pharma—demonstrating strategic investment in innovative cardiovascular therapies aligned with ambitious revenue goals. However, challenges persist as demonstrated by Amgen's Tavneos being linked to fatalities across Japan and the U.S., raising significant concerns about data integrity and pharmacovigilance. In contrast, Revolution Medicines' RAS inhibitor doubled survival rates in phase 3 pancreatic cancer trials. This breakthrough positions Revolution as an emerging leader in oncology therapeutics amidst fierce competition from companies aiming to improve drug tolerability and extend survival benefits. These narratives paint a picture of an industry poised for transformation—balancing scientific breakthroughs against regulatory challenges and financial pressures. As therapeutic modalities evolve—from oral biologics to advanced ADCs—the sector is set on course for substantial impacts on patient care and drug development pipelines. In summary, the pharmaceutical and biotech industries' focus on advancing therapeutic options through scientific innovation while navigating complex regulatory landscapes underscores an ongoing commitment to addressing unmet medical needs through new drug classes and targeted therapies. These efforts highlight trends toward personalized medicine and precision oncology that are likely to shape future trajectories in these dynamic fields.Support the show

For years in Nigerian politics, incumbency was seen as almost untouchable. Once you occupied political office, many believed securing another party ticket was only a formality. But the latest APC primaries across Nigeria have challenged that belief, as several serving lawmakers and political heavyweights lost their return tickets despite their influence and political structures. So, what really changed? Has the power of incumbency weakened, or are deeper political forces quietly reshaping the APC ahead of 2027? Today on Nigeria Daily, we examine why many incumbent office holders could not survive the APC primaries and what it could mean for Nigeria's political future.

In this episode of the Crack House Chronicles True Crime Podcast Donnie and Dale discuss the disappearance of Leanne Green. 17 year old Leanne Martha Leanne Green was picked up by her brother Lawson from her work at the Holiday Inn on April 15, 1987 in Dickson TN. They ran out of gas about a 1/2 mile later. A family stopped to help and Lawson rode with them to get gas. They were gone less than 10 minutes. She was gone when they returned. Her purse and the car keys were sitting on the seat of the unlocked car and there were no signs of a struggle. https://www.crackhousechronicles.com/ https://linktr.ee/crackhousechronicles https://www.tiktok.com/@crackhousechronicles https://www.facebook.com/crackhousechronicles Check out our MERCH! https://www.teepublic.com/user/crackhousechronicles SOURCES: https://www.yahoo.com/news/leanne-green-case-shattered-dickson-100152693.html https://charleyproject.org/case/martha-leanne-green https://www.reddit.com/r/UnresolvedMysteries/comments/drbv4h/the_disappearance_of_martha_leanne_green/ https://www.google.com/search?client=firefox-b-1-d&hs=sbZ&sca_esv=74f761a989b9a07f&sxsrf=ANbL-n5cD4dIyuTFttcKJijBYOv-p_B9IQ:1779028552694&udm=7&fbs=ADc_l-aN0CWEZBOHjofHoaMMDiKpmAsnXCN5UBx17opt8eaTX5ijYCyJdSZFM4mewRGuivYYa3mYl0ctDuDplBAp7RpJJiertViLIk7lwzDfFJvD79peka0NjzC5Fx4T6srURfKtb_0GUYremVy9HofmP0FCn_uKHmxhARKhXQ0MgMqEDoWaMXAzYRQKTe8ElbKXMe0y9u1uOPH3M_RVcCbdzjQCZetVeg&q=leanne+green+youtube&sa=X&ved=2ahUKEwiz2LbnxcCUAxV45ckDHb4tH_0QtKgLegQIFhAB&biw=1366&bih=635&dpr=1#fpstate=ive&vld=cid:27bb5a9d,vid:XIfWatTfk5o,st:0  

Dr. Mayank Gandhi, CEO of NEOK Bio, discusses the company's work on bispecific antibody drug conjugates and the limitations of conventional ADCs, which target a single antigen. Using a bispecific antibody to target two unique antigens on a tumor can address the shortcomings of earlier approaches by improving delivery of the toxic payload, overcoming tumor heterogeneity, and reducing off-target toxicity.  NEOK has drugs in development for prostate cancer, and lung, head, neck, and gastrointestinal tumors. The trend for ADCs is toward multi-specific and multi-payload drugs, though Mayank warns it is not a simple task to go from one to many in designing these drug conjugates. Mayank explains, "There have been a lot of advancements in the last couple of decades, and especially the last few years, in various modalities in the treatment of hematological cancers, as well as to a certain degree in solid tumors. However, for many, many solid tumors, there's still a high unmet need given the still significant outcome, poor outcomes that patients experience, particularly with patients having metastatic disease across a variety of solid tumors. Now, if you look at specific modality like ADC or antibody drug conjugates, which is where NEOK Bio is, there's been a renaissance, if you will, with this modality in the last five to six years, particularly after the approval of a drug called Enhertu, which targets HER2 mutation. Now, many ADCs have been approved with different payloads. And so definitely that's made a dent in a variety of tumors, particularly in hematological cancers and select solid tumors as well."   "Conventional ADCs thus far target one antigen or one target on a tumor. So it's an antibody-based approach. The antibody is typically pursuing one specific antigen that's usually an antigen that's expressed on tumors selectively versus normal tissue or normal cells. And then you have a linker and a payload, usually a toxic payload that's conjugated via a linker to the antibody. So that's an antibody drug conjugate construct."   "Thus far, all the ADCs approved have been targeting only one antigen with a couple of different payloads. And so our bispecific approach is targeting two different antigens. If we use a bispecific antibody that targets two unique antigens on the tumor, we have more than one place that a potential antibody can bind and deliver the toxic payload. And then we have made some very significant improvements or changes in the antibody itself." #NEOKBio #DrugDevelopment #Innovation #AntibodyDrugConjugates #ADC #Oncology #Biotech#Oncology #SolidTumors #BispecificADC #CancerResearch #TranslationalResearch #MedicalOncology #HematologyOncology #ClinicalTrials #Biotech #Pharma #DrugDevelopment #PrecisionOncology #TumorMicroenvironment #TargetedTherapy NEOKBio.com Download the transcript here

Dr. Mayank Gandhi, CEO of NEOK Bio, discusses the company's work on bispecific antibody drug conjugates and the limitations of conventional ADCs, which target a single antigen. Using a bispecific antibody to target two unique antigens on a tumor can address the shortcomings of earlier approaches by improving delivery of the toxic payload, overcoming tumor heterogeneity, and reducing off-target toxicity.  NEOK has drugs in development for prostate cancer, and lung, head, neck, and gastrointestinal tumors. The trend for ADCs is toward multi-specific and multi-payload drugs, though Mayank warns it is not a simple task to go from one to many in designing these drug conjugates. Mayank explains, "There have been a lot of advancements in the last couple of decades, and especially the last few years, in various modalities in the treatment of hematological cancers, as well as to a certain degree in solid tumors. However, for many, many solid tumors, there's still a high unmet need given the still significant outcome, poor outcomes that patients experience, particularly with patients having metastatic disease across a variety of solid tumors. Now, if you look at specific modality like ADC or antibody drug conjugates, which is where NEOK Bio is, there's been a renaissance, if you will, with this modality in the last five to six years, particularly after the approval of a drug called Enhertu, which targets HER2 mutation. Now, many ADCs have been approved with different payloads. And so definitely that's made a dent in a variety of tumors, particularly in hematological cancers and select solid tumors as well."   "Conventional ADCs thus far target one antigen or one target on a tumor. So it's an antibody-based approach. The antibody is typically pursuing one specific antigen that's usually an antigen that's expressed on tumors selectively versus normal tissue or normal cells. And then you have a linker and a payload, usually a toxic payload that's conjugated via a linker to the antibody. So that's an antibody drug conjugate construct."   "Thus far, all the ADCs approved have been targeting only one antigen with a couple of different payloads. And so our bispecific approach is targeting two different antigens. If we use a bispecific antibody that targets two unique antigens on the tumor, we have more than one place that a potential antibody can bind and deliver the toxic payload. And then we have made some very significant improvements or changes in the antibody itself." #NEOKBio #DrugDevelopment #Innovation #AntibodyDrugConjugates #ADC #Oncology #Biotech#Oncology #SolidTumors #BispecificADC #CancerResearch #TranslationalResearch #MedicalOncology #HematologyOncology #ClinicalTrials #Biotech #Pharma #DrugDevelopment #PrecisionOncology #TumorMicroenvironment #TargetedTherapy NEOKBio.com Listen to the podcast here

Editor-in-Chief of the Archives of Disease in Childhood, Dr Nick Brown, and Senior Editor of ADC, Dr Rachel Agbeko, bring you the monthly Atoms - the highlights of the May 2026 issue. Read it on the Archives of Disease in Childhood website: https://adc.bmj.com/content/111/5/i        Please listen to our regular podcasts and subscribe in Apple Podcasts, Google Podcasts, Stitcher and Spotify to get episodes automatically downloaded to your phone and computer. And if you enjoy the podcast, please leave us a review at https://podcasts.apple.com/gb/podcast/adc-podcast/id333278832 

We have results of the 24th National Dairy Challenge along with markets, ADC's recent comments, and testing status for states unaffected by bird flu.

What has competition enforcement looked like in Italy and Portugal over the past year? Saverio Valentino, Board Member of the Italian Antitrust Authority, joins Jaclyn Phillips to discuss AGCM's 2025 enforcement record, an ongoing digital sector investigation into Meta, and a whistleblower platform that has generated over 600 complaints since 2023. Next, Nuno Cunha Rodrigues, President of the Portuguese Competition Authority, speaks with Jeny Maier about a creative hospital merger remedy, AdC's research on AI and competition, and a consumer outreach initiative that took the authority beyond Lisbon. Listen to this episode to hear how two of Europe's most active competition agencies are approaching enforcement and advocacy in 2026. With special guests: Saverio Valentino, Board Member, AGCM (Italian Antitrust Authority) and Nuno Cunha Rodrigues, President, AdC (Portuguese Competition Authority) Related Links: Italian Antitrust Authority (AGCM) Portuguese Competition Authority (AdC) Hosted by: Jaclyn Phillips, Proskauer Rose and Jeny Maier, Axinn, Veltrop & Harkrider

Gäster: Jonas Dillner, Viktor Elsnitz, Thomas Eriksson, Hjalmar Lindgren, Erik Broström För 90SEK/mån får du 5 avsnitt i veckan:4 Vanliga AMK MORGON + AMK FREDAG med Isak Wahlberg Se till att bli Patron via webben och inte direkt i iPhones Patreon-app för att undvika Apples extraavgifter:Öppna istället din browser och gå till www.patreon.com/amkmorgon Önska Karakou till Gröna Lund!https://faq.gronalund.com/support/tickets/new Gå på Stand Up på Tunlandet i STHLMhttp://tunnlandet.beer Gå på Snälla Kom varje torsdag 19:00 på TROLL i STHLMhttps://www.instagram.com/snallakom/?hl=en Relevanta länkar: ...Deep Coverhttps://www.imdb.com/title/tt31121295/ ...Bugoniahttps://www.imdb.com/title/tt12300742/ ...Pete Hegsethhttps://media.newyorker.com/photos/6734f6ad4d9614360a5bb102/master/w_2560%2Cc_limit/Fisher-Lede-%2520Pete%2520Hegseth.jpg https://www.instagram.com/reels/DWXogNCiOzs/ ...Masked Singer-läckanhttps://www.expressen.se/noje/tv-och-streaming/sa-lackte-namnen-i-masked-singer-i-tv4/ https://www.aftonbladet.se/nojesbladet/a/9ppba9/sa-avslojade-tv4-masked-singer-lackan ...Masked Singerhttps://image-api.sr.se/v1/static/AA/5335/32a2bb7f-80f4-4a2f-93bc-fe5278b97259.jpg?w=1024&h=576&q=75 https://images.aftonbladet-cdn.se/v2/images/893fb7c9-1e21-458a-b96f-5ec4945b5d99?fit=crop&format=auto&h=1125&q=50&w=1500&s=f00e4fa3da57171d1b0f695f45855718c77446a8 ...maskmakaren Eva-Karinhttps://www.land.se/livet-pa-landet/eva-karin-gor-maskerna-till-masked-singer-i-en-verkstad-i-angermanland ...Lagt Kort Liggerhttps://www.google.com/search?sca_esv=816abb5a51ae04a7&sxsrf=ANbL-n6fBfEPme93sdPHTtHXXN_2GHnqrg:1774939914819&udm=2&fbs=ADc_l-aN0CWEZBOHjofHoaMMDiKpaEWjvZ2Py1XXV8d8KvlI3qbRMPzpk8hEvxCREXk87iqsvDNzoh7QYR1iPUJ9MsjH4aTulz5ChgSvEibTmVdYWcje5qQJXVPPgwEh8Sc_J6gyZxhFVdOc8KuIXoShtQ4dfwdfHfiNEYCA1Mpmj7hze2Jhzi8S1MsdO0QRbvmltZBn0wDO&q=lagt+kort+ligger+magnus&sa=X&ved=2ahUKEwiGhfu4xsmTAxUuUFUIHUcuB6EQtKgLegQIGRAB&biw=862&bih=741&dpr=1.75#sv=CAMSVhoyKhBlLV80SklWaEV2cXVZTkhNMg5fNEpJVmhFdnF1WU5ITToOOEdpanRscXplZ1J5YU0gBCocCgZtb3NhaWMSEGUtXzRKSVZoRXZxdVlOSE0YADABGAcgqfb8LUoIEAEYASABKAE ...Supersvararnahttps://www.svtplay.se/video/8PbMoJj/supersvararna/viveca-sundvall-malena-ivarsson-och-leif-silbersky?video=visa&position=1745 ...Treutigerhttps://sv.wikipedia.org/wiki/Harald_Treutiger Låtarna som spelades var:24 Karat - Kartellen, 24KClosing Time - Semisonic Alla låtar finns i AMK Morgons spellista här:https://open.spotify.com/user/amk.morgon/playlist/6V9bgWnHJMh9c4iVHncF9j?si=so0WKn7sSpyufjg3olHYmg

This episode I am reading from Admir Serrano's book 'Nights on the Other Side: How I Discovered My Immortality' Nights on the Other Side” is a book that invites us to look at life from a different perspective: more lucid, more open, and less fearful. Admir describes out-of-body experiences with clarity, combining his personal testimony with scientific references. But above all, he conveys the sense that we are not alone and that we are something more than we believe. Bio I am a Brazilian-American researcher, writer and lecturer on paranormal phenomena such as out-of-body experiences (OBEs), near-death experiences (NDEs), deathbed visions (DBVs), after- death communication (ADC), reincarnation, mediumship and the afterlife. And an unabashed believer in our survival of physical death and the immortality of the spirit. My interest in these subjects was triggered after I began having spontaneous OBEs, back in the year 2000, and I wanted to understand the phenomenon. Since then, I have had hundreds of lucid and amazing experiences which have proven to me beyond a shadow of a doubt that we are immortal beings. Aware of the sadness that death of a loved one can cause – and I have experienced it myself – I have made it my life's mission to spread the notion that there is no death, that only the body dies, and since we are not our body, we survive death – unscathed. For my own edification regarding the dynamics of physical death, I have worked as a hospice volunteer providing spiritual support to terminally ill patients as they waited for their time to cross over to the other side of life. And this is what death is, a change of worlds, the end of one mode of living, the physical, to the beginning of a spiritual existence. I have bachelor's degrees in psychology and liberal studies, and a master's in theology. I am an avid reader with a broad interest in world and religious history, anthropology, geography, world affairs, and the humanities. I have written five books in my native Portuguese language on death, dying and the afterlife, and two in English on related topics. I write and lecture in both languages, as well as Spanish, the third language I speak. I live in Homestead, Florida, with my wife, two daughters and my lovely grandson. https://www.admirserrano.com/ https://www.pastliveshypnosis.co.uk/https://www.patreon.com/ourparanormalafterlifeMy book 'Verified Near Death Experiences' https://www.amazon.com/dp/B0DXKRGDFP Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

This week I'm talking to Admir Serrano about his book 'Nights on the Other Side: How I Discovered My Immortality' Nights on the Other Side” is a book that invites us to look at life from a different perspective: more lucid, more open, and less fearful. Admir describes out-of-body experiences with clarity, combining his personal testimony with scientific references. But above all, he conveys the sense that we are not alone and that we are something more than we believe. Bio I am a Brazilian-American researcher, writer and lecturer on paranormal phenomena such as out-of-body experiences (OBEs), near-death experiences (NDEs), deathbed visions (DBVs), after- death communication (ADC), reincarnation, mediumship and the afterlife. And an unabashed believer in our survival of physical death and the immortality of the spirit. My interest in these subjects was triggered after I began having spontaneous OBEs, back in the year 2000, and I wanted to understand the phenomenon. Since then, I have had hundreds of lucid and amazing experiences which have proven to me beyond a shadow of a doubt that we are immortal beings. Aware of the sadness that death of a loved one can cause – and I have experienced it myself – I have made it my life's mission to spread the notion that there is no death, that only the body dies, and since we are not our body, we survive death – unscathed. For my own edification regarding the dynamics of physical death, I have worked as a hospice volunteer providing spiritual support to terminally ill patients as they waited for their time to cross over to the other side of life. And this is what death is, a change of worlds, the end of one mode of living, the physical, to the beginning of a spiritual existence. I have bachelor's degrees in psychology and liberal studies, and a master's in theology. I am an avid reader with a broad interest in world and religious history, anthropology, geography, world affairs, and the humanities. I have written five books in my native Portuguese language on death, dying and the afterlife, and two in English on related topics. I write and lecture in both languages, as well as Spanish, the third language I speak. I live in Homestead, Florida, with my wife, two daughters and my lovely grandson. https://www.admirserrano.com/ https://www.pastliveshypnosis.co.uk/https://www.patreon.com/ourparanormalafterlifeMy book 'Verified Near Death Experiences' https://www.amazon.com/dp/B0DXKRGDFP Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.